of bridgebio. >> what we're able to do now is to say, "you have this mutation, and you're very likely to have this disease, and this is how severe it's going to be." for diseases that are really that easy to describe, those are easier in our mind to drug, than diseases like diabetes or heart failure, where there could be many different causes for the disease. >> reporter: this is like woody guthrie's disease, huntington's? >> that's right. huntington disease is a classic genetic disease. sickle celanemia, tay-sachs disease. these are the types of disease we're talking about.te >> rep bridgebio has 17 drug development projects in its diversified portfolio. >> it's very difficult to convince an investor that this sickle cell or this tay-sachs or this huntington approathe right approach, so you've got to what one has to do to attract the vast majority of capital in gethe world to the early s space like this is to say, "look, it's true, we're going to take mostly losses, but the houple of wins are going to pay us out fse losses. in the movie industry, for instance, one would not finance o